Research programme: AAV-based gene therapies - Bristol-Myers Squibb/uniQure

Drug Profile

Research programme: AAV-based gene therapies - Bristol-Myers Squibb/uniQure

Alternative Names: AAV-S100A1; AMT 120; S100A1

Latest Information Update: 14 Apr 2016

Price : $50

At a glance

  • Originator Bristol-Myers Squibb; uniQure
  • Class Calcium binding proteins; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cardiovascular disorders

Most Recent Events

  • 04 Apr 2016 UniQure plans to file an IND application for Cardivascular disorders
  • 06 Apr 2015 uniQure and Bristol-Myers Squibb enter into a collaboration agreement to develop AAV based gene therapies for cardiovascular disorders
  • 11 Aug 2014 Pharmacodynamics data from a preclinical trial in Cardiovascular disorders released by uniQure
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top